8-K filed April 20, 2026, 7:59 PM ET ticker KLRA CIK 0002096997

other material confidence high sentiment positive materiality 0.85

Kailera Therapeutics closes IPO raising $718.8M; issues 44.9M shares at $16.00

Kailera Therapeutics, Inc.

Closed IPO of 44,921,875 shares at $16.00 per share, including full exercise of underwriters' option for 5,859,375 additional shares.
Gross proceeds of $718.8 million before underwriting discounts and offering expenses.
Amended certificate of incorporation: authorized 800M shares of common stock and 10M shares of undesignated preferred stock.
Adopted classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.
Amended bylaws to require advance notice for stockholder proposals and director nominations, and limit action by written consent.

item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-164040
form_type: 8-K
ticker: KLRA
cik: 0002096997
company_name: Kailera Therapeutics, Inc.
filed_at: 2026-04-20T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.492233+00:00
generated_at: 2026-05-15T05:23:54.737561+00:00
sec_items: ["5.03", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-164040
json_url: https://secwatch.observer/filing/0001193125-26-164040.json
markdown_url: https://secwatch.observer/filing/0001193125-26-164040.md
text_url: https://secwatch.observer/filing/0001193125-26-164040.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/d137434d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

4155bd13189cc843ab47d9dad5700997e7fa77f8

Kailera Therapeutics, Inc.: Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums (effective 2026-04-20).

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

576b1f2b897b05910763691e7575a49fd2a16275

Kailera Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments (effective 2026-04-20).

On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

QLEP

Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE

Quantum Leap Acquisition Corp May 6, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.

Filing page SEC filing

MCAH

Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30

Mountain Crest Acquisition 6 Corp. May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.

Filing page SEC filing

COAG

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

Hemab Therapeutics Holdings, Inc. May 4, 2026, 7:59 PM ET other_material Items 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Filing page SEC filing

RREV

RRE Ventures Acquisition Corp. prices and closes $250M IPO; units begin trading on Nasdaq

RRE Ventures Acquisition Corp. May 1, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On April 28, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on April 29, 2026.

Filing page SEC filing

DMAA

SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

Drugs Made In America Acquisition Corp. May 1, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month

Filing page SEC filing

BAFN

BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO

BayFirst Financial Corp. April 30, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 2.02, 5.02, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

Comparable filing

On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-164040

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.